Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Patient Preferences for Outcomes of Hormonal Agents and Chemotherapy in Combination With Androgen Deprivation Therapy

NCT05381311 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT05381311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05381311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Patient Preferences for Outcomes of Hormonal Agents and Chemotherapy in Combination With Androgen Deprivation Therapy
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Observational
Overall status
Completed
Start date
September 3, 2021
Completion date
December 11, 2022
Enrollment
1,020 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer, prostate cancer